Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe

Benefit for Neoadjuvant Chemotherapy Seen in Very Young Patients With Triple-Negative and Luminal-Like Breast Cancer

TOP - February 2013 VOL 6, NO 1 published on March 4, 2013 in Breast Cancer

Young women with triple-negative and luminal-type breast cancer were more likely to respond to neoadjuvant chemotherapy than were older women with these cancers, and improved outcomes were observed for young women with luminal-A–like tumors who achieved a pathologic complete response (pCR) versus those who did not. The study suggests that neoadjuvant chemotherapy is beneficial for young women with triple-negative and luminal-type breast cancer, even those with favorable biological features that include hormone receptor positivity (HR+) and human epidermal growth factor 2–negative (HER2–) disease.

“Breast cancer is less common in women age 35 or younger, and some data suggest that these younger patients have a worse prognosis. This is not only because they tend to have more aggressive breast cancers, but because tumors that arise in younger women appear to have different biological features,” stated Sibylle Loibl, MD, PhD, associate professor at the University of Frankfurt, Germany.

The meta-analysis that Loibl and colleagues reported at the CTRC-AACR San Antonio Breast Cancer Symposium included a total of 8949 women from 8 German studies. All women had operable or locally advanced nonmetastatic breast cancer and received neoadjuvant chemotherapy. Among these women, 704 were aged 35 years or younger. pCR and disease-free survival (DFS) were compared for the younger patients (aged ≤35 years) versus women aged 36 to 50 years and women aged 51 years or older.

A greater percentage of younger women had triple-negative breast cancer (32% for younger women, about 25% for those aged 26-50 years, and 21% for those aged 51 years and older). Compared with older women, a smaller percentage of younger women had luminal-A–type breast cancer (27% vs 21%, respectively).

pCR was significantly higher in younger women compared with older women: 23.6% versus 17.5% of women in the 36- to 50-year-old age group and 13.5% of those aged 51 years and older (P <.001); this difference in pCR was confined to triple-negative and luminal-like breast cancer (HR+/HER2–). More in-depth analysis showed that this difference was restricted to women with triple-negative breast cancer: the pCR rate was 45% for younger patients versus 31% for older patients (P <.001). For all patients, regardless of subtype of breast cancer, DFS and local recurrence-free survival were significantly worse for the very young patients (aged ≤35 years) compared with middle-aged patients (aged 36-50 years; P = .031 and P = .018, respectively). No difference in DFS according to age was observed among patients who achieved pCR. However, DFS was significantly worse among women who failed to achieve pCR.

Tumor biology appeared to be impor-tant in predicting pCR and survival in younger women. Age but not pCR predicted DFS in women with luminal-A–type cancer. However, the worst DFS rate was seen among those women with luminal-A–type breast cancer who were younger than age 35 years and did not achieve pCR. The most favorable DFS was observed among younger women who did achieve pCR.

Loibl said the investigators were surprised to find that younger women with luminal-type cancer (HR+ and HER2–) who achieved pCR had improved survival compared with patients with nonpathologic CR. “This is not seen in other age groups, indicating that breast cancer in the young women is chemosensitive, even when it is a luminal-type breast cancer,” she stated.

Reference
Loibl S, Jackisch C, Gade S, et al. Neoadjuvant chemotherapy in the very young 35 years of age or younger. Presented at: 2012 CTRC-AACR San Antonio Breast Cancer Symposium; December 4-8, 2012; San Antonio, TX.

Related Items
Olaparib Extends Disease-Free Survival in Patients with Early-Stage Breast Cancer and BRCA Mutation
William King
TOP - November 2021 Vol 14, No 7 published on November 10, 2021 in Breast Cancer
Tucatinib plus Trastuzumab and Capecitabine Triplet Maintains Survival Benefit in HER2-Positive Metastatic Breast Cancer: Updated Results from HER2CLIMB Trial
Charlie Dawson
TOP - September 2021 Vol 14, No 5 published on September 7, 2021 in Breast Cancer
Cryoablation Appears Safe and Effective in Low-Risk, Early-Stage Breast Cancer
William Ackerman
TOP - July 2021 Vol 14, No 4 published on July 20, 2021 in Breast Cancer
Pembrolizumab plus Chemotherapy Improves Progression-Free Survival in Metastatic TNBC
Patricia Stewart
TOP - May 2021 Vol 14, No 3 published on May 14, 2021 in Breast Cancer
Abemaciclib plus Endocrine Therapy Offers Invasive Disease–Free Survival Benefit in Patients with High-Risk, HR-Positive, Early-Stage Breast Cancer
Patricia Stewart
TOP - May 2021 Vol 14, No 3 published on May 14, 2021 in Breast Cancer
Breast Cancer Year in Review Introduction
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Retrospective Analysis Provides Insight into Treatment-Emergent Neutropenia Among Patients with Metastatic Breast Cancer Treated with Ribociclib or Palbociclib
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Concurrent Use of Medications with Potential Drug–Drug Interactions: Real-World Analysis of Patients Treated with CDK4/6 Inhibitors
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Abemaciclib plus Fulvestrant Provides Statistically Significant Benefit as First- and Second-Line Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Preliminary Results from a Phase 2 Trial of Fulvestrant/Palbociclib as First-Line Therapy in Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Endocrine-Sensitive Advanced Breast Cancer
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Last modified: July 22, 2021